EASD, JDRF and Novo Nordisk join forces in diabetes research

Published: 15-Dec-2006
Sustainability Research & Development


The European Association for the Study of Diabetes (EASD), the Juvenile Diabetes Research Foundation (JDRF) and Novo Nordisk plan two new diabetes research initiatives in Europe.

The first initiative will focus on type 1 diabetes and will receive funding from all three parties, while the second initiative will focus on type 2 diabetes and will receive funding only from EASD and Novo Nordisk.

This non-profit and private-sector partnership builds upon research programmes launched by the three parties in 2000. Together, the three partners have committed Euro 3.6 million (US$4.5 m dollars) over the next three years.

The type 1 diabetes programme will provide research grants within a broad range of research areas, including projects aimed at finding a cure for diabetes. The type 2 programme will support research into diabetes in children and youth with a special focus on the link between obesity and type 2 diabetes.

Professor Ele Ferrannini, president of EASD and EFSD, commented on the importance of increasing funding for diabetes research in Europe: "We have a lot of diabetes expertise in Europe, but the level of funding of the research is inadequate. I hope this partnership between EASD, JDRF and Novo Nordisk will inspire both governments and industry to increase their contributions to basic research into diabetes."

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Read more
Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Research & Development

Novo Nordisk's Wegovy effective in obese patients, Phase IIIb data suggests

A 7.2mg dose of semaglutide triggered an average weight loss of 21% in obese patients during a 72 week period
Manufacturing

Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m

Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases
Regulatory

Anti-IL-21 monoclonal antibody licensed by Almirall

NN-8828, the IL-21 blocker, is exclusively owned by Almirall and will be used to treat immune inflammatory dermatological diseases
Manufacturing

BioInnovation adds eight early-stage companies to acceleration programme

Lomo, Novozymes and Amalus are all among the eight countries selected by BII to join its acceleration programme for early-stage companies looking to strike out into the pharmaceutical industry
Manufacturing

Data shows insulin icodec meets additional endpoints in adults with type 2 diabetes in phase 3a trials

The results were shared at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA)
Subscribe now